Almesh Kadakol Selected Research

esculetin

11/2017	Esculetin ameliorates vascular perturbation by intervening in the occupancy of H2BK120Ub at At1, At2, Tgfβ1 and Mcp1 promoter gene in thoracic aorta of IR and T2D rats.
9/2017	Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications.
8/2017	Esculetin ameliorates hepatic fibrosis in high fat diet induced non-alcoholic fatty liver disease by regulation of FoxO1 mediated pathway.
12/2016	Esculetin: A phytochemical endeavor fortifying effect against non-communicable diseases.
10/2015	Insulin sensitizing and cardioprotective effects of Esculetin and Telmisartan combination by attenuating Ang II mediated vascular reactivity and cardiac fibrosis.
5/2015	Esculetin attenuates alterations in Ang II and acetylcholine mediated vascular reactivity associated with hyperinsulinemia and hyperglycemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Almesh Kadakol Research Topics

Disease

4	Insulin Resistance 11/2017 - 10/2015
4	Fibrosis (Cirrhosis) 08/2017 - 10/2015
2	Diabetic Cardiomyopathies 11/2017 - 09/2017
2	Inflammation (Inflammations) 08/2017 - 12/2016
2	Diabetic Nephropathies (Diabetic Nephropathy) 06/2017 - 12/2016
2	Neoplasms (Cancer) 06/2017 - 12/2016
2	Obesity 06/2017 - 12/2016
2	Renal Insufficiency (Renal Failure) 12/2016 - 11/2015
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2016 - 05/2015
1	Cardiomyopathies (Cardiomyopathy) 09/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 08/2017
1	Non-alcoholic Fatty Liver Disease 08/2017
1	Atherosclerosis 06/2017
1	Noncommunicable Diseases 12/2016
1	Nervous System Diseases (Neurological Disorders) 12/2016
1	Type 2 Diabetes Mellitus (MODY) 10/2015
1	Hyperinsulinism (Hyperinsulinemia) 05/2015
1	Hyperglycemia 05/2015
1	Breast Neoplasms (Breast Cancer) 01/2015
1	Neoplasm Metastasis (Metastasis) 01/2015

Drug/Important Bio-Agent (IBA)

6	esculetinIBA 11/2017 - 05/2015
3	Fibronectins (Fibronectin)IBA 09/2017 - 01/2015
2	Telmisartan (Micardis)FDA Link 09/2017 - 10/2015
2	Histones (Histone)IBA 09/2017 - 11/2016
2	CollagenIBA 08/2017 - 01/2015
1	AntioxidantsIBA 08/2017
1	FatsIBA 08/2017
1	Proteins (Proteins, Gene)FDA Link 08/2017
1	UbiquitinIBA 06/2017
1	Proteasome Endopeptidase Complex (Proteasome)IBA 06/2017
1	Lysine (L-Lysine)FDA Link 12/2016
1	ChromatinIBA 12/2016
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 12/2016
1	PhytochemicalsIBA 12/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2016
1	coumarinIBA 12/2016
1	Monocyte Chemoattractant ProteinsIBA 12/2016
1	Angiotensin-Converting Enzyme 2IBA 11/2015
1	Angiotensin IIIBA 11/2015
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2015
1	Insulin (Novolin)FDA Link 10/2015
1	Acetylcholine (Acetylcholine Chloride)FDA Link 05/2015
1	Streptozocin (Streptozotocin)FDA Link 05/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2015
1	InterleukinsIBA 01/2015
1	Cell Adhesion MoleculesIBA 01/2015
1	Interleukin-8 (Interleukin 8)IBA 01/2015
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2015
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2015
1	VitronectinIBA 01/2015
1	Cyclin D1IBA 01/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2015
1	Epidermal Growth Factor (EGF)IBA 01/2015
1	CurcuminIBA 01/2015

Therapy/Procedure

1	Therapeutics 08/2017